Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupBrain Tumors (ped.)Neuro-OncologyDiseaseGliomaSubgroupBRAF mutationEpendymomaHER2+WHO grade 1 and 2ICD10C71.-MeSHAstrocytomaEpendymomaGliomaSequenceChemotherapyChemo-substanceLomustineProcarbazineTioguaninTovorafenibTrastuzumab DeruxtecanVincristineChemo-substanceLomustineProcarbazineTioguaninTovorafenibTrastuzumab DeruxtecanVincristineChemo-substanceLomustineProcarbazineTioguaninTovorafenibTrastuzumab DeruxtecanVincristineChemo-substanceLomustineProcarbazineTioguaninTovorafenibTrastuzumab DeruxtecanVincristineNo. Substances14 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimNo. Substances24Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlBleedingDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HeadacheHepatotoxicityIncrease AminotransferasesInfectionsNeutropeniaPruritusPyrexiaRashSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorAter JLKilburn LBKrex DDiseaseAnaplastisches Ependymom, wiederkehrend, HER2 aktiviertProgressives oder residuelles Low-Grade Gliom bei Kindern, WHO Grad 1+ 2, Alter unter 10, ErstliniePädiatrisches Low-Grade-Gliom (pLGG), 6 Monate bis 25 Jahren, rezidiviert/refraktär, aktivierende BRAF-AlterationOriginChildren's National Hospital, Washington, DC, USA, FIREFLY-1 trialDepartment of Neurosurgery, Technische Universität Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, GermanyUniversity of Texas MD Anderson Cancer Center, Houston, COG StudieProtokolle in Überarbeitung 3 protocols foundTioguanin 30 / Procarbazine 50 / Lomustine 110 / Vincristine 1.5, Glioma (PID604 V1.1)Tovorafenib 380, Glioma (PID3274 V1.0)Trastuzumab Deruxtecan 5,4, Ependymoma (PID3270 V1.0)
